Durect Corporation (DRRX)
Add to Watchlists Create an AlertDRRX Key Stats
| Income Statement | |
| Revenue TTM | 16.04M |
| Revenue Quarterly YoY Growth | -89.92% |
| EPS Diluted TTM | -0.2105 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -19.81M |
| Profitability | |
| Gross Profit Margin Quarterly | 60.08% |
| Profit Margin Quarterly | -124.8% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 86.93M |
| Enterprise Value | 66.18M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 2.593 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | -3.403M |
| Return on Equity | -59.09% |
DRRX News
- FDA Painkiller Abuse Concerns Creating Opportunity For Pfizer May 20
- Eyeing Business Models and Practices that are Sustainable and Value-Creating in ... May 16
- No Relief in Sight for Pain Therapeutics Investors Fool May 12
- No Relief in Sight for Pain Investors May 12
- Pain Therapeutics, Durect fall on Remoxy review May 10
- MARKET PULSE-Hess Corp, Ubiquity Networks, Unilife, ServiceSource May 10
- Pain Therapeutics, Durect Fall as Pfizer Evaluates Pill May 10
- BRIEF-Pain Therapeutics down 43 pct, DURECT down 36.5 pct premarket May 10
- Pfizer yet to decide on Pain Therapeutics' painkiller May 10
- DURECT Announces Update on Remoxy® PR Newswire May 10
DRRX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Durect Corporation is up 7.99% over the last year vs S&P 500 Total Return up 27.96%, Acura Pharmaceuticals down 14.44%, and Pain Therapeutics down 24.73%.
DRRX Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these DRRX related companies
Pro Ratings for DRRX
Pro Report PDF for DRRX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Pro Strategies Featuring DRRX
Did Durect Corporation make it into our Pro Portfolio Strategies?
DRRX Profile
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Other DRRX Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| DRRX | 0.8531 | -0.04 | -4.15% | 86.93M |